All News
Docs' Liking for Knee Injection Tied to Industry Payments
d
MedPage Today
Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found.
Read Article
Night Splinting for Carpal Tunnel (3.24.2023)
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
Read Article
Anti-mesangial autoantibodies in IgA nephropathy
d
EurekAlert!
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.
Read Article
Updated AAV Treatment Recommendations
AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
https://t.co/gQr92GpE5j https://t.co/SGDh1uNg2b
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 3804 runners from 2019, 2021 Chicago marathon looked at assocn betw marathons running and arthritis. Prevalence of hip / knee arthritis was 7.3%. Hip/Knee OA was assoc w/ prior injury/surgery, older age, FamHx, & BMI (not #marathons, mileage) https://t.co/P91dR9kSgY https://t.co/p7hFKEbGOw
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB
Links:
Dr. John Cush RheumNow ( View Tweet)
Anti-mesangial autoantibodies in IgA nephropathy
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.
https://t.co/owOoAMrtxW https://t.co/RZMGkagcWJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH
Links:
Dr. John Cush RheumNow ( View Tweet)
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Dr. John Cush RheumNow ( View Tweet)
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/NJK7uJIqsV https://t.co/CQStRUUkUn
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/0fXUVv0sCR https://t.co/fT6iAOPOpc
Links:
Dr. John Cush RheumNow ( View Tweet)
LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication.
🧵1of2 https://t.co/VZL9qJu9kF
Lupus Research LupusResearch ( View Tweet)
Updated AAV Treatment Recommendations
AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb
Links:
Dr. John Cush RheumNow ( View Tweet)
Our old friend, hydroxychloroquine
Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus.
https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S
Links:
Dr. John Cush RheumNow ( View Tweet)
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years
@RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT
Links:
Dr. John Cush RheumNow ( View Tweet)
